多重分析市场份额，规模，趋势，行业分析报告，技术;逐型（蛋白质多重测定，核酸多重测定，基于细胞的多重测定）;通过申请，通过最终用户;按地区;分部预测，2022 - 2030

报告摘要

全球多路复用分析市场于2021年的30.3亿美元估值，预计预测期内复合年增长率为7.2％。慢性疾病的患病率增加，特别是癌症，其中常用多重测试，是驾驶全球多路复用试验市场的主要驱动因素之一。

了解有关此报告的更多信息：request for sample pages

Numerous advantages along with rapid breakthroughs in nanotechnology are expected to propel the global industry forward. In addition, the use of multiplex tests for cancer diagnosis, immune system disorders, as well as other factors is driving the market.

Furthermore, expanded government funding increased research efforts in the pharmaceutical and biotechnology sectors, and a growing focus on enhancing experiment efficiency is projected to move the global industry forward. The increased acknowledgment of the multifactorial nature of illnesses and pathological circumstances such as cancer and Alzheimer's disease has demanded the development of a cost-effective and time-saving technology for assessing many analyzers in a single sample.

This aspect drives the global market for multiplex tests. New development prospects are projected to arise in the coming years as researchers work to improve and cost-effectively supply highly dense Nano array technology. Companion diagnostics are quickly becoming an essential part of individualized treatment, both in number and utilization in disease areas. Companion diagnostics are projected to develop rapidly shortly based on the current product pipeline. This rise in companion diagnostics is projected to significantly impact the worldwide multiplex assays industry.

However, the high costs of purchasing and using multiplex assays are significant impediments to the expansion of the global market. Moreover, the global market is likely to be restrained by tight government criteria for multiplex assay approvals throughout the projected period. The industry is expected to be constrained by the increased demand for healthcare systems to deliver services at an affordable cost. Furthermore, the complexity of clinical trial methodologies is thought to hinder the market.

Industry Dynamics

Growth Drivers
2021年4月,圣杯,医疗启动集中乐动娱乐官网on the early life-saving diagnosis of various malignancies, was bought by Illumina. However, during the European Commission's current regulatory examination, Illumina will hold GRAIL as a separate entity. In addition, in February 2021, Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company, was bought by Thermo Fisher Scientific Inc., a provider of scientific apparatus, reagents & consumables, and software & services to healthcare, life science, and other laboratories. Thus, significant players' acquisitions and advancements are the factors that are boosting the market growth during the forecast period.

此外，在2021年8月，Becton，Dickinson和公司推出了BD Cor系统，这是一种革命性的完全自动化的高通量诊断系统。该系统采用机器人和样本管理软件算法来建立自动化病毒疾病分析的新标准。因此，用于治疗各种疾病的产品的发射正在提高多重测定市场的增长。

报告细分

The market is primarily segmented based on type, technology, application, end-user, and region.

By Type	By Technology	通过申请	By End-User	按地区
蛋白质多重测定 平面蛋白质测定 Bead-Based Protein Assays Other Protein Assays Nucleic Acid Multiplex Assays 平面核酸测定 Bead-Based Nucleic Acid Assays Other Nucleic Acid Assays Cell-Based Multiplex Assays	流式细胞仪 荧光检测 Luminescence Multiplex Real-Time PCR Others	研究& Development 药物发现与发展 Biomarker Discovery & Validation Clinical Diagnostics 传染性疾病 Cancer 心血管疾病 Autoimmune Diseases Nervous System Disorders Metabolism & Endocrinology Disorders Others	Pharmaceutical & Biotechnology Companies 医院和研究机构 Reference Laboratories Others	北美（美国，加拿大） 欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) 拉丁美洲（巴西，墨西哥，阿根廷） 中东和非洲（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

Insight by End-Use

Based on the end-user segment, the pharmaceutical & biotechnology companies segment is the most significant revenue contributor in the global market in 2021 and is expected to retain its dominance in the foreseen period. Pharmaceutical and biotechnology firms are likely to dominate the worldwide multiplex assays market. This substantial percentage can be due to pharmaceutical firms' rising use of these in drug research and development and biotechnology companies' increased focus on creating biosimilars and monoclonal antibodies.

Geographic Overview

In terms of geography, North America had the highest share in 2021. The market for multiplex assays in North America is the largest globally. The North American market is driven by an increase in the number of immunoassay tests conducted and the prevalence of Alzheimer's patients. Due to the apparent government's endeavors in enhancing precision medicine in advance with strategic partners among the critical players in competing for multiplex assay development, the U.S. is expected to dominate the North American multiplex assay industry.

此外，市场正在受到美国人均收入上涨的推动。老年人口的崛起和许多行业球员的存在推动了美国。到北美多路复用分析市场的顶端。由于研发支出增加和癌症患者增加，加拿大市场主要扩大。

此外，亚太地区在2021年在全球市场中见证了高中复合，预计未来几年以最快的速度增长。该行业受阿尔茨海默患者的普遍率和不断增长的患者人口的推动。印度和中国是全球市场的两个最重要的贡献者。此外，亚太多路复用试验市场由印度和中国的许多制药业务驱动，以及研发投资的显着增加。

竞争洞察力

Some of the major players operating in the global market include Luminex Corporation, Enzo Life Sciences, Inc., Promega Corporation, Meso Scale Diagnostics, Quanterix, Thermo Fisher Scientific Inc., Qiagen N.V., Illumina, Inc, Shimadzu Biotech, Abcam plc, Bio-Rad Laboratories, Inc., Becton, AYOXXA Biosystems GmbH, Bio-Techne Corporation, Dickinson and Company, Randox Laboratories, Merck KGaA, Agilent Technologies, Inc., Olink, DiaSorin S.p.A., Antigenix America, Inc., Siemens Healthineers, PerkinElmer, Inc., Boster Biological Technology, Seegene, and Cayman Chemical Company among others.

多重测定市场Report Scope

报告属性	细节
2021年市场尺寸值	USD 3.03 billion
Revenue forecast in 2030	USD 5.57 billion
CAGR	7.2% from 2022 - 2030
Base year	20.21
Historical data	20.18 - 2020
预测期	20.22- 2030
Quantitative units	Revenue in USD million and CAGR from 2022 to 2030
Segments covered	By Type, By Technology, By Application, By End-Use, By Region
Regional scope	北美、欧洲、亚太地区、Latin America; Middle East & Africa
Key Companies	Luminex Corporation, Enzo Life Sciences, Inc., Promega Corporation, Meso Scale Diagnostics, Quanterix, Thermo Fisher Scientific Inc., Qiagen N.V., Illumina, Inc, Shimadzu Biotech, Abcam plc, Bio-Rad Laboratories, Inc., Becton, AYOXXA Biosystems GmbH, Bio-Techne Corporation, Dickinson and Company, Randox Laboratories, Merck KGaA, Agilent Technologies, Inc., Olink, DiaSorin S.p.A., Antigenix America, Inc., Siemens Healthineers, PerkinElmer, Inc., Boster Biological Technology, Seegene, and Cayman Chemical Company